Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026

Get updates on Theralase Technologies Inc. delivered in your email.

Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > FERRING’s gene therapy: Not what doctors want

View:

Post by ScienceFirst on Aug 31, 2023 11:05am

FERRING’s gene therapy: Not what doctors want

Despite the US jv deal (500M$US + 5-8% of royalties for the US market alone):

https://www.ferring.com/royalty-pharma-and-ferring-pharmaceuticals-enter-into-us-500-million-royalty-agreement-for-new-intravesical-gene-therapy-adstiladrin/

... FERRING's Adstiladrin gene therapy is not the holy-grail. Not what doctors ordered.

https://www.evaluate.com/vantage/articles/analysis/spotlight/renewed-push-early-bladder-cancer

Ferring's Adstiladrin has joined Keytruda with a US approval, but it might not be the answer doctors are looking for.

192

Comment

Comment by Eoganacht on Aug 31, 2023 11:15am

Unlike Ruvidar PDT! As Dr. Kamat said at the conclusion of our phase 1 trial: "The clinical data presented by Dr. Kulkarni suggests that the Theralase PDT treatment option may be just what the doctor ordered.” https://theralase.com/theralase-successfully-completes-phase-ib-non-muscle-invasive-bladder-cancer-clinical-study/

155

Comment

Theralase Technologies Inc.

The Market Update

< Previous bulletin

Next bulletin >

A daily snapshot of everything
from market open to close.

Connect with V.TLT

INVESTORS & MEDIA OVERVIEW FINANCIAL FILINGS PRESENTATIONS MEDIA FACT SHEETS MANAGEMENT

Investor Presentation

The Road to Saving Lives: Clinical Study Underway

Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
Best-in-class treatment for NMIBC (according to interim clinical data)
NMIBC (Non-Muscle-Invasive Bladder Cancer)

FACT SHEET

The Watchlist

< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
Best-in-class treatment for NMIBC (according to interim clinical data)
NMIBC (Non-Muscle-Invasive Bladder Cancer)

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250

Become a member today, It's free!

Sign In

Send my password